Difference between revisions of "WSI21-134"

From MGH Learn Pathology
(Edited automatically from page WSI21-134.)
 
(72 intermediate revisions by 12 users not shown)
Line 1: Line 1:
{{dziOrderStudySet
+
{{ServiceRequest
|order_date=July 06, 2021 01:07:32 PM
+
|intent=order
|user=Em99
+
|category=409073007
|class_name=Study Set
+
|priority=routine
|status=Created
+
|code=study
|collection_name=Cytopathology
+
|orderDetail=order
|class_type=Cytology
+
|authoredOn=July 06, 2021 01:07:32 PM
|collection_topic=Pleural, Pericardial, and Peritoneal Fluids
+
|requester=Em99
|requested_by=IAC
+
|locationCode=learn
|restrict_access=Public
+
|access=public
 +
|subject=MGH
 +
|performer=MGH
 +
|supportingInfo=Cytology
 +
|requisition=Cytology
 +
|reasonCode=Pleural, Pericardial, and Peritoneal Fluids
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Si787
 +
|authoredOn=March 10, 2022 10:38:21 AM
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=Jun 03, 2022 13:47:05
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=Jul 15, 2022 18:09:02
 
}}
 
}}
 
{{status
 
{{status
|requester=Em99
+
|status=active
|authoredOn=July 06, 2021 01:07:29 PM
+
|identifier=WSI21-134
|status=Created
+
|requester=Iac0
 +
|authoredOn=Jul 15, 2022 18:09:10
 
}}
 
}}
 
{{status
 
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 
|requester=Iac0
 
|requester=Iac0
|authoredOn=Jul 28, 2021 14:15:18
+
|authoredOn=Jul 15, 2022 18:12:11
|status=Submitted
+
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 19, 2022 14:19:17
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 20, 2022 16:54:23
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 20, 2022 17:32:46
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 20, 2022 18:25:18
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 14:36:18
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Jul 22, 2022 14:36:48
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ndk6
 +
|authoredOn=Sep 27, 2022 13:09:33
 
}}
 
}}
 
{{status
 
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Sep 27, 2022 17:05:55
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Rl391
 +
|authoredOn=Sep 28, 2022 11:22:35
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Sep 30, 2022 14:30:49
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 07, 2022 15:33:26
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Pab16
 +
|authoredOn=Oct 12, 2022 21:07:27
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 17, 2022 20:27:34
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 17, 2022 20:30:58
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 19, 2022 12:57:05
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Oct 24, 2022 17:35:59
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ndk6
 +
|authoredOn=Nov 01, 2022 11:30:20
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Nov 15, 2022 14:16:58
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Nov 15, 2022 15:19:00
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Eh441
 +
|authoredOn=Nov 18, 2022 14:15:33
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Eh441
 +
|authoredOn=Nov 18, 2022 14:23:26
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Dec 05, 2022 15:53:51
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Dec 08, 2022 21:32:04
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Dec 13, 2022 19:52:11
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 18:55:16
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:01:40
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:14:54
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:16:48
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:17:14
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:21:42
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Feb 08, 2023 14:17:31
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Feb 09, 2023 17:52:56
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Feb 13, 2023 17:27:54
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ez278
 +
|authoredOn=Feb 26, 2023 19:14:22
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Ez278
 +
|authoredOn=Feb 26, 2023 19:25:54
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:06:20
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:07:00
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 03, 2023 14:08:31
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Mar 23, 2023 16:47:54
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Cfh13
 +
|authoredOn=Mar 23, 2023 16:56:22
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 12:59:08
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 12:59:54
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 13:00:59
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=Apr 06, 2023 18:30:14
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Ndk6
 +
|authoredOn=Apr 13, 2023 20:04:39
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Aja51
 +
|authoredOn=May 15, 2023 12:43:08
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 
|requester=Mlz8
 
|requester=Mlz8
|authoredOn=Aug 03, 2021 14:21:57
+
|authoredOn=May 19, 2023 19:05:08
|status=Recreated
+
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 +
|requester=Mlz8
 +
|authoredOn=May 19, 2023 19:08:00
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-134
 +
|requester=Iac0
 +
|authoredOn=May 25, 2023 20:12:03
 
}}
 
}}
 
{{status
 
{{status
 +
|status=submitted
 +
|identifier=WSI21-134
 
|requester=Mlz8
 
|requester=Mlz8
|authoredOn=Aug 03, 2021 14:23:48
+
|authoredOn=Sep 01, 2023 11:51:57
|status=Submitted
 
 
}}
 
}}

Latest revision as of 06:52, September 1, 2023


Request type Study
Subspecialty Cytology
Set Cytology
Topic Pleural, Pericardial, and Peritoneal Fluids
Presenter MGH


Toggle columns: Diagnosis

CaseClinical historyRequester
CaseClinical historyRequester

Case 1


18-year-old male. History of glioblastoma. Iac0

Case 2


80yo M with left-sided pleural effusion Mlz8

Case 3


69yo F with pleural effusion Mlz8

Case 4


48M kidney failure. Pleura FNA. Iac0

Case 5


Over 90-year old male with significant asbestos exposure Lcm51

Case 6


Pericardial effusion and history of parotid mass and atrial mass Mlz8

Case 7


33F. Peritoneal carcinomatosis. Iac0

Case 8


45 y/old F Long Hx of ESRD post kidney transplant. New effusion duodenal mass and peritoneal nodules. Lcm51

Case 9


41M. History of clear cell sarcoma of finger. Iac0

Case 10


73y/old F with right pleural effusion and flank pain. Aja51

Case 11


60 y/old F with new pleural effusion and prior "soft tissue" tumor in the arm. Aja51

Case 12


79 yo male Ndk6

Case 13


50 yo female with history of metastatic carcinoma with bilateral pleural effusions Ndk6

Case 14


65 yo M with a history of myeloma. Cfh13

Case 15


HISTORY OF MULTIPLE MYEOMA WITH PLASMACYTOMA. NOW HAS PLEURAL EFFUSIONS Pab16

Case 16


78 YO male with h/o adenocarcinoma of pyloric antrum and ascites Ndk6

Case 17


Hx triple negative breast cancer Est105

Case 18


18-year-old man Eh441

Case 19


55 yo F with a remote history of breast carcinoma. Cfh13

Case 20


55 yo M with chronic pleural effusion. Cfh13

Case 21


52 yo F with acute respiratory failure in the setting of cocci and remote myeloma. Cfh13

Case 22


68yo man with a history of oncocytic thyroid carcinoma (metastatic to one lymph node) and clear cell renal cell carcinoma Ez278

Case 23


68 yo woman with an ovarian mass Cfh13

Case 24


73 yo man with ascites noted on surveillance following a Whipple for pancreatic carcinoma Cfh13

Case 25


27 yo F with unrescetable thymic carcinoma Ndk6

Case 26


80-year-old man Njc35

Case 27


49M ascites fluid Mlz8

Case 28


69F. Pleural based mass. Iac0

Case 29


73 yo male Dc679

Case 30


34 yo male with left empyema and c/f lymphoma Ndk6

Case 31


75 yo male Ndk6

Case 32


72 yo female with thyroid cancer with recurrent right pleural effusion Ndk6

Case 33


67F. Pelvic mass. Pelvic ascites. Iac0

Case 34


62F. History of papillary thyroid carcinoma. Now with pleural effusion. Iac0

Case 35


20M. History of CNS lymphoma. Iac0

Case 36


87 YOF with with recurrent advanced pulmonary adenocarcinoma who recently developed myocarditis after Pembrolizumab and pleural effusion. Tz046
Showing 1 to 36 of 36 entries